Orexo’s Partner Gesynta Pharma Initiates Phase II Study of OX-MPI in Systemic Sclerosis
Uppsala, Sweden – January 26, 2021 – Orexo’s partner, Gesynta Pharma, today announces the initiation of the Phase II study of OX-MPI (GS-248) in patients with systemic sclerosis. Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), aims to develop a treatment for microvascular diseases in chronic inflammatory conditions.
Systemic sclerosis, a debilitating autoimmune disease that causes serious damage to the Microvasculature. The purpose of this study is to investigate the safety of OX-MPI (GS-248) and its efficacy on Raynaud’s phenomenon and peripheral blood flow in the patient group. The results of this Phase II trial are expected late 2021 and will serve as a basis for future clinical trials in systemic sclerosis and potentially other inflammatory diseases. For more information on the Phase II study, Gesynta Pharma´s press release is attached.